Evidence map›Paper›PMID 38303921›Full record

ReviewInternational journal of heart failure2024

Optimizing Heart Failure Management: A Review of the Clinical Pharmacist Integration to the Multidisciplinary Health Care Team.

Esteban Zavaleta-Monestel, Sebastián Arguedas-Chacón, Alonso Quirós-Romero, José Miguel Chaverri-Fernández, Bruno Serrano-Arias, José Pablo Díaz-Madriz, Jonathan García-Montero, Mario Osvaldo Speranza-Sanchez

Open access · diamondAbstract readReview
In one paragraph

Review in International journal of heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Esteban Zavaleta-MonestelPharmacy Department, Hospital Clínica Bíblica, San José, Costa Rica.ORCID https://orcid.org/0000-0003-3726-0079
Sebastián Arguedas-ChacónPharmacy Department, Hospital Clínica Bíblica, San José, Costa Rica.ORCID https://orcid.org/0000-0001-8547-7745
Alonso Quirós-RomeroPharmacy Department, Hospital Clínica Bíblica, San José, Costa Rica.ORCID https://orcid.org/0000-0001-5507-2034
José Miguel Chaverri-FernándezFaculty of Pharmacy, University of Costa Rica, San José, Costa Rica.ORCID https://orcid.org/0000-0002-8367-7740
Bruno Serrano-AriasPharmacy Department, Hospital Clínica Bíblica, San José, Costa Rica.ORCID https://orcid.org/0000-0002-9571-0878
José Pablo Díaz-MadrizPharmacy Department, Hospital Clínica Bíblica, San José, Costa Rica.ORCID https://orcid.org/0000-0003-3637-6168
Jonathan García-MonteroPharmacy Department, Hospital Clínica Bíblica, San José, Costa Rica.ORCID https://orcid.org/0009-0009-5088-0257
Mario Osvaldo Speranza-SanchezHeart Failure Program, Hospital Clínica Bíblica, San José, Costa Rica.ORCID https://orcid.org/0000-0002-6947-0735
Universidad Bíblica Latinoamericana · CRUniversidad de Ciencias Medicas · CRUniversidad de Costa Rica · CR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) stands as a prevalent chronic ailment, imposing a substantial burden on global healthcare systems due to recurrent hospitalizations, intricate management, persistent symptoms, and polypharmacy challenges. The augmentation of patient safety and treatment efficacy across various care stages, facilitated by a multidisciplinary HF team inclusive of a clinical pharmacist, emerges as paramount. Evidence underscores that the collaborative engagement of a physician and a clinical pharmacist engenders proficient and secure management, forestalling avoidable adversities stemming from drug reactions and prescription inaccuracies. This synergistic approach tailors treatments optimally to individual patients. Post-discharge, the vulnerability of HF patients to re-hospitalization looms large, historically holding sway as the foremost cause of 30-day readmissions. Diverse strategies have been instituted to fortify patient well-being, leading to the formulation of specialized transitional care programs that shepherd patients effectively from hospital to outpatient settings. These initiatives have demonstrably curtailed readmission rates. This review outlines a spectrum of roles assumed by clinical pharmacists within the healthcare cohort, spanning inpatient care, transitional phases, and outpatient services. Moreover, it traverses a compendium of studies spotlighting the affirmative impact instigated by integrating clinical pharmacists into these fields.

Indexed as

Clinical pharmacistHeart failureMedication adherencePharmaceutical services

Identifiers

PMID38303921
PMCPMC10827703
OpenAlexW4388985352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.